Zynaxsis Inc. regulatory update

The Malvern, Penn., company received notice of allowance for a U.S. patent covering its Zyn-Linker drug delivery molecules to reduce cellular adhesions. ZNXS is investigating the use of Zyn-Linkers incorporating chemotherapeutics to treat ovarian cancer and other tumors that kill by spreading within a body cavity. ...